Eylea HD Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Eylea HD market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the increased adoption of biologic therapies, rising awareness of eye care, regulatory approvals and support, a growing aging population, and strong recommendations from physicians.

Market growth during the forecast period can be attributed to the rising prevalence of eye disorders, the increasing incidence of age-related macular degeneration, the growing prevalence of ophthalmic conditions, advancements in healthcare systems, and improved awareness and early detection. Key trends in the forecast period include the development of innovative drug delivery systems, advancements in combination therapies, integration of advanced eye testing systems in hospitals and ophthalmologic centers, the use of artificial intelligence in the detection of diabetic retinopathy, and technological advancements in the field.

The increasing prevalence of eye disorders is expected to drive the growth of the Eylea HD market. Eye disorders include conditions such as refractive errors, cataracts, glaucoma, macular degeneration, diabetic retinopathy, and retinal diseases, all of which affect vision and cause discomfort. Factors such as an aging population, prolonged screen time, environmental influences, genetic predispositions, and the rising rates of chronic diseases contribute to the growing prevalence of eye disorders. Eylea HD (aflibercept injection 8 mg) is a treatment used for eye disorders involving abnormal blood vessel growth or fluid leakage in the retina. It is a high-dose version of the original Eylea (aflibercept 2 mg). For example, in November 2024, the World Health Organization reported that the pooled prevalence of childhood myopia over the past 12 years (up to 2022) was 5.23%, with higher rates in females (4.90%) compared to males (3.94%). As such, the increasing prevalence of eye disorders is driving the growth of the Eylea HD market.

The growing adoption of personalized medicines is expected to accelerate the growth of the Eylea HD market. Personalized medicine tailors treatments based on a patient’s genetic, environmental, and lifestyle factors to improve safety and efficacy. This approach is becoming more prevalent due to advances in genomics, better diagnostics, increased treatment effectiveness, reduced side effects, rising patient demand, and regulatory support, which all contribute to long-term cost savings. Eylea HD is an example of personalized medicine, providing targeted treatment for retinal diseases based on individual patient characteristics. For instance, in February 2024, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized treatments for patients with rare diseases, up from six in 2022. Consequently, the rise of personalized medicine is driving the growth of the Eylea HD market.

A significant trend in the Eylea HD market is the development of innovative biologic medications that aim to improve treatment outcomes, enhance efficacy, and reduce the need for frequent injections. Biologic medications, which are made from living organisms or their cells, are designed to treat various diseases, including immune-related conditions, cancer, and chronic illnesses such as diabetes. In August 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for Eylea HD (aflibercept) Injection 8 mg, a biologic medication for treating wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR). This approval highlights the company’s commitment to advancing retinal disease treatments by improving efficacy, patient outcomes, and reducing the frequency of injections, benefiting those affected by these conditions.

Major players in the eylea hd market are Regeneron Pharmaceuticals Inc and Bayer AG.

North America was the largest region in the eylea HD market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in eylea HD report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the eylea HD market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Eylea HD is an advanced formulation of aflibercept, a vascular endothelial growth factor (VEGF) inhibitor used to treat specific retinal diseases. Delivered via intravitreal injection, Eylea HD contains a higher dosage (8 mg) compared to the standard Eylea (2 mg), allowing for extended treatment intervals and reducing the need for frequent injections while maintaining similar efficacy and safety profiles.

The main indications for Eylea HD include wet age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, and macular edema. Wet AMD is a chronic eye condition caused by abnormal blood vessel growth under the retina, which can lead to vision loss. Eylea HD is distributed through various channels, including hospital pharmacies, specialty pharmacies, and online pharmacies. It is used by a variety of end users, such as hospitals, clinics, ambulatory surgery centers (ASCs), and home care providers.

The eylea HD market research report is one of a series of new reports that provides eylea HD market statistics, including the eylea HD industry global market size, regional shares, competitors with the eylea HD market share, detailed eylea HD market segments, market trends, and opportunities, and any further data you may need to thrive in the eylea HD industry. This eylea HD market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The eylea HD market consists of sales of injections, delivery devices, companion diagnostic tools, single-dose vials, and biosimilars and generics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.